I-Mab Announces Participation at Jefferies and Piper Conferences in November
ROCKVILLE, MD, U.S. and SHANGHAI, China, November 6, 2023 – I-Mab (Nasdaq: IMAB) (the “Company”), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:
Jefferies London Healthcare Conference (In Person)
| Presentation Time | Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST) |
| Presenters | Mr. Raj Kannan, CEO Dr. John Hayslip, CMO |
| Webcast link | https://wsw.com/webcast/jeff287/imab/1828028 The webcast will also be available under “Event Calendar” on I-Mab’s IR website at http://ir.i-mabbiopharma.com/ |
| Meetings | One-on-one and small group meetings: Nov 14 – 16, 2023 |
| Management Participants | Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Jefferies representative.
Piper Sandler 35th Annual Healthcare Conference (In Person)
| Presentation Time | Thursday, November 30th at 8:30 a.m. EST |
| Presenters | Mr. Raj Kannan, CEO Dr. John Hayslip, CMO |
| Meetings | One-on-one and small group meetings: Nov 28 – 30, 2023 |
| Management Participants | Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Piper Sandler representative.
###
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab’s innovative pipeline is driven by internal R&D’s Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, X, formerly known as Twitter, and WeChat.